Table 2.
Toxicity in prospective studies comparing chemoradiotherapy with weekly or three-weekly cisplatin vs. radiotherapy alone (4–7, 10–17).
| Concurrent cisplatin regimen | Study number | No. of pts. evaluable for acute toxicity | Gr. 3-4 acute toxicity during CRTa | No. of toxic deaths (during CRT or within 30 days after completion) | 30-day mortality (during CRT or within 30 days after completion), No. of cases | No. of pts. evaluable for late toxicity | Late toxicity | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anemia | Thrombocytopenia | Leukopenia | Neutropenia | Febrile neutropenia | Mucositis and/or stomatitis | Xerostomia | Dysphagia (pharynx/esophagus) | Nausea and/or vomiting | Weight loss | Laryngeal toxicity | Nephrotoxicity | Neurotoxicity | Ototoxicity | Skin toxicity | Diarrhea | Infection | gr. 3-4 overall prevalencee | gr. 1-2 xerostomia | gr. 3-4 xerostomia | gr. 3-4 dysphagia | gr. 3-4 subcutaneous fibrosis | ||||||
| Weekly low-dose | 1. (10) | 39 | 3% | - | - | 10% | - | 21% | - | - | 23% | 21% | - | 0% | - | - | - | - | - | - | - | 30c | 6c | - | - | - | 3c |
| 2. (11) | 77 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | - | - | - | - | - | - | |
| 3. (12) | 149 | - | - | - | - | - | - | - | - | 3% | - | 4% | 1% | 1% | - | - | 0% | 3% | 3 | - | - | - | - | - | - | - | |
| 4. (13) | 65 | - | - | - | - | 9% | 35% | - | - | - | - | - | - | - | - | 23% | - | - | 2 | 2 | - | - | - | - | - | - | |
| Three-weekly high-dose | 5. (4) | 204 | 3% | - | - | - | - | 30% | 2% | 25% | 20% | - | 3% | 2% | 5% | - | 7% | 1% | 6% | 2 | - | 201 | 20% | 55%f | 3% | 7% | 1% |
| 6. (5) | 167 | - | - | 16% | 13% | - | 41% | 14% | 12% | 12% | - | 1% | - | - | - | 1%b | - | - | - | - | - | - | - | - | - | - | |
| 7. (6) | 87 | 20% | 3% | 46% | - | - | 49% | - | - | 17% | - | - | 9% | - | - | 8% | - | - | 4 | - | - | - | - | - | - | - | |
| 8. (7) | 171 | - | - | - | - | - | 43% | - | 35% | 20% | - | 18% | 4%b | 5% | - | 7% | - | 4% | 9 | 9 | 157d | - | 67%d | 6%d | 16%d | 6%d | |
| 9. (15) | 44 | 2% | 4% | 21% | 9% | - | 34% | 0% | 5% | 23% | 16% | 0% | - | 0% | - | 2% | 0% | 5% | 1 | 3 | - | - | - | - | - | - | |
a
Adelstein: grade III-V acute toxicity.
b
Forastiere: renal or genitourinary toxicities; Bernier: skin and connective tissue fibrosis.
c
Data from Bachaud et al. (16)
d
Data from Forastiere et al. (14)
e
On a per-patient basis (this information was not provided in the Bachaud et al. trial)
f
Data from Cooper et al., 2012, related to a population of 193 patients eligible for late toxicity assessment (17).
No., number; pts., patients; gr., grade; CRT, chemoradiotherapy